Buscar resultados de ensayos clínicos

Patrocinado por

Carcinoid Syndrome - 25 Studies Found

Estado Estudiar
Withdrawn Nombre del estudio: Study of Panitumumab in the Treatment of Carcinoid Syndrome
Condición: Carcinoid Syndrome
Fecha: 2010-07-28
Intervenciones: Drug: Panitumumab Panitumumab will be given by intravenous infusion at a dose of 9 mg/kg on day 1 of stu
Completed Nombre del estudio: Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome
Condición: Symptoms of Carcinoid Syndrome
Fecha: 2010-04-12
Intervenciones:
  • Drug: Low Dose LX1606 - Day 1 (start)

Terminated Nombre del estudio: Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome
Condición: Malignant Carcinoid Syndrome
Fecha: 2004-09-22
Intervenciones:
  • Drug: lanreotide Autogel (somatostatin analogue)
Completed Nombre del estudio: Effects of Serotonin Excess on Bone in Carcinoid Syndrome
Condición: Carcinoid Syndrome
Fecha: 2011-08-26
Completed Nombre del estudio: Telotristat Etiprate for Carcinoid Syndrome Therapy
Condición: Carcinoid Syndrome
Fecha: 2014-02-12
Intervenciones:
  • Drug: Telotristat etiprate tablets (250 mg)

Terminated Nombre del estudio: Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome
Condición: Carcinoid Syndrome
Fecha: 2009-04-20
Intervenciones: Drug: Octreotide short acting octreotide
Completed Nombre del estudio: An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
Condición: Carcinoid Syndrome
Fecha: 2008-10-15
Intervenciones:
  • Drug: Lanreotide deep s.c. inj
Terminated Nombre del estudio: Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome
Condición: Carcinoid Syndrome
Fecha: 2009-11-24
Intervenciones: Drug: BIM 23A760 BIM 23A760 is a solution at a concentration of 5 mg/mL ready for subcutaneous injection
Completed Nombre del estudio: TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)
Condición: Carcinoid Syndrome
Fecha: 2012-08-30
Intervenciones:
  • Drug: Telotristat etiprate tablets (250 mg)

Active, not recruiting Nombre del estudio: Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
Condición: Carcinoid Syndrome
Fecha: 2013-12-31
Intervenciones: Drug: Telotristat etiprate tablets (250 mg) Other Name: LX1606
Next >>>